

**Measles Virus, MVs/Massachusetts.USA/19.11/2 [G3]**

**Catalog No. NR-52255**

**Product Description:**

Measles virus (MeV), MVs/Massachusetts.USA/19.11/2 [G3] was collected from a throat swab in May 2011 in Massachusetts, USA and was isolated on August 28, 2014. NR-52255 lot 70033299 was produced by infecting *Cercopithecus aethiops* kidney epithelial cells with human signaling lymphocytic activation molecule (Vero E6-hSLAM) with the deposited material and incubating in Dulbecco's Modified Eagle's Medium (ATCC® 30-2002™) supplemented with 2% fetal bovine serum (ATCC® 30-2020™) for 2 days at 37°C with 5% CO<sub>2</sub>.

**Passage History:**

VE6-hSLAM(3)/VE6-hSLAM(2) (Centers for Disease Control and Prevention/BEI Resources); VE6-hSLAM = *Cercopithecus aethiops* kidney epithelial cells with human signaling lymphocytic activation molecule

**Lot: 70033299**

**Manufacturing Date: 05FEB2021**

| TEST  | SPECIFICATIONS  | RESULTS   |
|---|---|---|
| Identification by Infectivity in Vero E6-hSLAM Cells  | Syncytia formation  | Syncytia formation  |
| Next-Generation Sequencing (NGS) Using Illumina® iSeq™ 100 Platform   | ≥ 98% identity with MeV, MVs/Massachusetts.USA/19.11/2 [G3] (GenBank: JN599002.1)       | 100% identity with MeV, MVs/Massachusetts.USA/19.11/2 [G3] (GenBank: JN599002.1)        |
| Amplification of MeV Sequence by RT-PCR   | ~ 630 base pair amplicon  | ~ 630 base pair amplicon  |
| Sequencing of Species-Specific Region (450 nucleotides)   | ≥ 98% identity with MeV, MVs/Massachusetts.USA/19.11/2 [G3] (GenBank: JN599002.1)       | 100% identity with MeV, MVs/Massachusetts.USA/19.11/2 [G3] (GenBank: JN599002.1)        |
| Titer by TCID <sub>50</sub> Assay in Vero E6-hSLAM Cells by Cytopathic Effect <sup>1</sup> (4 days at 37°C and 5% CO <sub>2</sub> )   | Report results  | 1.6 × 10 <sup>5</sup> TCID <sub>50</sub> per mL   |
| <b>Sterility (21-day incubation)</b><br>Harpo's HTYE broth, 37°C and 26°C, aerobic <sup>2</sup><br>Trypticase Soy broth, 37°C and 26°C, aerobic<br>Sabouraud broth, 37°C and 26°C, aerobic<br>Sheep blood agar, 37°C, aerobic<br>Sheep blood agar, 37°C, anaerobic<br>Thioglycollate broth, 37°C, anaerobic<br>DMEM with 10% FBS, 37°C, aerobic | No growth<br>No growth<br>No growth<br>No growth<br>No growth<br>No growth<br>No growth | No growth<br>No growth<br>No growth<br>No growth<br>No growth<br>No growth<br>No growth |
| <b>Mycoplasma Contamination</b><br>Agar and broth culture (14-day incubation at 37°C)<br>DNA detection by PCR of extracted Test Article nucleic acid  | None detected<br>None detected  | None detected<br>None detected  |

<sup>1</sup>The Tissue Culture Infectious Dose 50% (TCID<sub>50</sub>) endpoint is the 50% infectious endpoint in cell culture. The TCID<sub>50</sub> is the dilution of virus that under the conditions of the assay can be expected to infect 50% of the culture vessels inoculated, just as a Lethal Dose 50% (LD<sub>50</sub>) is expected to kill half of the animals exposed. A reciprocal of the dilution required to yield the TCID<sub>50</sub> provides a measure of the titer (or infectivity) of a virus preparation.

<sup>2</sup>Atlas, Ronald M. *Handbook of Microbiological Media*. 3rd ed. Ed. Lawrence C. Parks. Boca Raton: CRC Press, 2004, p. 798.

/Heather Couch/

Heather Couch

19 MAY 2021

Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

